Search research articles
Contact Us
Filters
Showing results (41-50 of 62) with videos related to
Page
of 7
Sort By:
Frontiers in Microbiology
|
May 21, 2019
Probiotic Potential and Safety Evaluation of <i>Enterococcus faecalis</i> OB14 and OB15, Isolated From Traditional Tunisian Testouri Cheese and Rigouta, Using Physiological and Genomic Analysis
Olfa Baccouri, Amine Mohamed Boukerb, Leila Ben Farhat, et al.
Organic Letters
|
March 25, 2005
Novel 3',6'-anhydro and N12,N13-bridged glycosylated fluoroindolo[2,3-a]carbazoles as topoisomerase I inhibitors. Fluorine as a leaving group from sp3 carbon
Mark G Saulnier, David R Langley, David B Frennesson, et al.
Bioorganic & Medicinal Chemistry Letters
|
February 9, 2008
2-(1H-Imidazol-4-yl)ethanamine and 2-(1H-pyrazol-1-yl)ethanamine side chain variants of the IGF-1R inhibitor BMS-536924
Mark G Saulnier, David B Frennesson, Mark D Wittman, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 24, 2008
Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors
Kurt Zimmermann, Mark D Wittman, Mark G Saulnier, et al.
Bioorganic & Medicinal Chemistry Letters
|
April 20, 2010
Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one
Upender Velaparthi, Mark G Saulnier, Mark D Wittman, et al.
Journal of Medicinal Chemistry
|
January 7, 2026
Enhancing the Oral Bioavailability of a Poorly Soluble Pan-CK2 Kinase Inhibitor: Leveraging a Phosphate Prodrug Strategy to Overcome Dissolution-Limited Absorption and Improve Systemic Exposure during Dose Escalation
Murugaiah A M Subbaiah, Naveen Manjunath, Thangeswaran Ramar, et al.
Bioorganic & Medicinal Chemistry Letters
|
February 24, 2007
Discovery and initial SAR of 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-ones as inhibitors of insulin-like growth factor 1-receptor (IGF-1R)
Upender Velaparthi, Mark Wittman, Peiying Liu, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 20, 2015
9H-Carbazole-1-carboxamides as potent and selective JAK2 inhibitors
Kurt Zimmermann, Xiaopeng Sang, Harold A Mastalerz, et al.
Journal of Medicinal Chemistry
|
September 4, 2008
Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity
Upender Velaparthi, Mark Wittman, Peiying Liu, et al.
Journal of Medicinal Chemistry
|
June 8, 2026
Drug Delivery Strategy Exploiting Amino Acid Prodrugs: Improving Oral Bioavailability and Overcoming Nonlinear Pharmacokinetic Challenges Following Dose Escalation of a CK2 Inhibitor with Poor Solubility
Murugaiah A M Subbaiah, Thangeswaran Ramar, Mathiazhagan Annadurai, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 62) with videos related to
Sort By:
Page
of 7
Frontiers in Microbiology
|
May 21, 2019
Probiotic Potential and Safety Evaluation of <i>Enterococcus faecalis</i> OB14 and OB15, Isolated From Traditional Tunisian Testouri Cheese and Rigouta, Using Physiological and Genomic Analysis
Olfa Baccouri, Amine Mohamed Boukerb, Leila Ben Farhat, et al.
Organic Letters
|
March 25, 2005
Novel 3',6'-anhydro and N12,N13-bridged glycosylated fluoroindolo[2,3-a]carbazoles as topoisomerase I inhibitors. Fluorine as a leaving group from sp3 carbon
Mark G Saulnier, David R Langley, David B Frennesson, et al.
Bioorganic & Medicinal Chemistry Letters
|
February 9, 2008
2-(1H-Imidazol-4-yl)ethanamine and 2-(1H-pyrazol-1-yl)ethanamine side chain variants of the IGF-1R inhibitor BMS-536924
Mark G Saulnier, David B Frennesson, Mark D Wittman, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 24, 2008
Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors
Kurt Zimmermann, Mark D Wittman, Mark G Saulnier, et al.
Bioorganic & Medicinal Chemistry Letters
|
April 20, 2010
Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one
Upender Velaparthi, Mark G Saulnier, Mark D Wittman, et al.
Journal of Medicinal Chemistry
|
January 7, 2026
Enhancing the Oral Bioavailability of a Poorly Soluble Pan-CK2 Kinase Inhibitor: Leveraging a Phosphate Prodrug Strategy to Overcome Dissolution-Limited Absorption and Improve Systemic Exposure during Dose Escalation
Murugaiah A M Subbaiah, Naveen Manjunath, Thangeswaran Ramar, et al.
Bioorganic & Medicinal Chemistry Letters
|
February 24, 2007
Discovery and initial SAR of 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-ones as inhibitors of insulin-like growth factor 1-receptor (IGF-1R)
Upender Velaparthi, Mark Wittman, Peiying Liu, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 20, 2015
9H-Carbazole-1-carboxamides as potent and selective JAK2 inhibitors
Kurt Zimmermann, Xiaopeng Sang, Harold A Mastalerz, et al.
Journal of Medicinal Chemistry
|
September 4, 2008
Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity
Upender Velaparthi, Mark Wittman, Peiying Liu, et al.
Journal of Medicinal Chemistry
|
June 8, 2026
Drug Delivery Strategy Exploiting Amino Acid Prodrugs: Improving Oral Bioavailability and Overcoming Nonlinear Pharmacokinetic Challenges Following Dose Escalation of a CK2 Inhibitor with Poor Solubility
Murugaiah A M Subbaiah, Thangeswaran Ramar, Mathiazhagan Annadurai, et al.
Page
of 7